Midazolam In Sodium Chloride Injection, Solution
NDC Package 68083-618-10
Package Information
Midazolam In Sodium Chloride injection is midazolam in 0.9% Sodium Chloride Injection is indicated: • Continuous intravenous infusion for sedation of intubated and mechanically ventilated adult, pediatric, and neonatal patients as a component of anesthesia or during treatment in a critical care setting. This formulation utilizes a injection, solution delivery system. Marketed by Gland Pharma Limited, this product is identified by NDC 68083-618 and is authorized under FDA application ANDA218993.
Identification & Billing
- RxCUI: 2541170 - midazolam 50 MG in 50 mL Injection
- RxCUI: 2541170 - 50 ML midazolam 1 MG/ML Injection
- RxCUI: 2541170 - midazolam 50 MG per 50 ML Injection
- RxCUI: 2541171 - midazolam 100 MG in 100 mL Injection
- RxCUI: 2541171 - 100 ML midazolam 1 MG/ML Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 68083 - Gland Pharma Limited
- 68083-618 - Midazolam In Sodium Chloride
- 68083-618-10 - 10 POUCH in 1 CARTON / 1 BAG in 1 POUCH / 50 mL in 1 BAG
- 68083-618 - Midazolam In Sodium Chloride
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68083-618-10 identifies a specific commercial package of 10 pouch in 1 carton / 1 bag in 1 pouch / 50 ml in 1 bag of Midazolam In Sodium Chloride, a human prescription drug labeled by Gland Pharma Limited. This injection, solution is formulated for intravenous use and contains midazolam hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Gland Pharma Limited on August 12, 2024. The current certification is valid through December 31, 2026.
How is this Gland Pharma Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68083061810. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.